Frankfurt
09.10.26 | 15:25
15,500 Euro
-0,64 % -0,100
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 15 | SEC Filings | ||
| 23.06. | Fortress Biotech, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Fortress Biotech GAAP EPS of $2.82, revenue of $16.04M misses by $0.3M | 4 | Seeking Alpha | ||
| 14.05. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Fortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 862 | GlobeNewswire (Europe) | ZYCUBO approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million... ► Artikel lesen | |
| FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
| 31.03. | Fortress Biotech, Inc.: Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights | 852 | GlobeNewswire (Europe) | ZYCUBOapproved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205... ► Artikel lesen | |
| 30.03. | Fortress Biotech, Inc.: Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million | 474 | GlobeNewswire (Europe) | MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing... ► Artikel lesen | |
| 23.02. | Fortress Biotech, Inc.: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million | 594 | GlobeNewswire (Europe) | MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium... ► Artikel lesen | |
| 16.01. | Weekly Buzz: Lyra Therapeutics Slashes Jobs; FDA Okays Fortress Biotech's ZYCUBO; Boston Scientific To Acquire Penumbra; BriaCell Therapeutics On Watch | 1.041 | AFX News | NEW BRUNSWICK (dpa-AFX) - This week, the biotech sector saw a steady stream of high-impact news, including a major workforce reduction and a fresh round of regulatory clearances spanning diabetes... ► Artikel lesen | |
| 13.01. | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States | 1.003 | GlobeNewswire (Europe) | Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million... ► Artikel lesen | |
| 14.11.25 | Fortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 1.014 | GlobeNewswire (Europe) | Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received... ► Artikel lesen | |
| 21.10.25 | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout | 437 | GlobeNewswire (Europe) | MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 247,70 | +0,04 % | Stryker Corporation: Stryker announces leadership succession | Portage, Michigan, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Kevin Lobo to transition to Executive Chair of the Board of DirectorsCurrent President and COO Spencer Stiles appointed Chief Executive OfficerLeadership... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 668,50 | +0,30 % | Kampf gegen Hautkrebs: Wie Vidac Pharma, Biofrontera und Regeneron an verschiedenen Stellen ansetzen | Auf der Jahrestagung der Europäischen Akademie für Dermatologie und Venerologie in Wien standen zuletzt neue Ansätze für die großflächige Behandlung von Hautschäden im Fokus. Der Kampf gegen Hautkrebs... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,400 | -0,39 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity | Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735
Monthly and Every-Other-Week Subcutaneous Regimens to also... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,800 | +1,03 % | Intellia Therapeutics-Aktie: Sind 80 US$ möglich? | Die Intellia-Therapeutics-Aktie notiert aktuell bei 12,37 US$ und damit mehr als -90% unter ihrem bisherigen Rekordhoch. Nach dem Ausbruch aus dem langjährigen Abwärtstrend versucht der Biotech-Titel... ► Artikel lesen | |
| TEMPUS AI | 63,60 | +0,39 % | Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom? | ||
| NUREXONE BIOLOGIC | 0,363 | -5,47 % | 7 Jahre USA, 10 Jahre EU: Warum Biogen, Novartis und NurExone auf den Orphan-Drug-Pfad setzen | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,151 | +3,61 % | Pacific Biosciences Collaborates With TychoBio For AI-powered RNA Data Creation; Shares Up | ||
| IMMUNITYBIO | 9,400 | +0,21 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,360 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| GINKGO BIOWORKS | 11,610 | -0,04 % | What's Going on With Ginkgo Bioworks Stock on Friday? | ||
| IOVANCE BIOTHERAPEUTICS | 13,020 | -0,15 % | Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call | ||
| CYTOMX THERAPEUTICS | 2,236 | -2,36 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 2,790 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates | Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward... ► Artikel lesen | |
| BIOMEA FUSION | 1,415 | 0,00 % | Brookline Capital initiates Biomea Fusion stock with buy rating | ||
| LIANBIO | - | - | LianMedical (Formerly Known as LianBio) Announces Completion of Merger Between LianBio and LianMedical | • Combined company to operate as LianMedical
• LianMedical to focus on advancing patient access to innovative medical technologies in China and other Asia Pacific markets
PRINCETON, N.J. & SHANGHAI--(BUSINESS... ► Artikel lesen |
FORTRESS BIOTECH INC PREF gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 15,500 Euro und damit -0,64 % im Minus. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTRESS BIOTECH INC PREF finden Sie auf Wallstreet Online.